Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?
In the following report, we describe a case of alkaline phosphatase (ALP) elevation occurring during treatment with alectinib (Alecensa™), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastatic disease exhibited a rapid and significant response within a very short period to alectinib therapy, accompanied by a rapid increase of ALP to more than six times the upper limit of normal (grade 3) ALP, decreasing to within normal limits within 3 weeks after initiation of therapy without any dose modification.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Current oncology (Toronto, Ont.) - 29(2021), 1 vom: 31. Dez., Seite 173-177 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shalata, Walid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALK mutation |
|---|
| Anmerkungen: |
Date Completed 24.03.2022 Date Revised 24.03.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/curroncol29010016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335843468 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335843468 | ||
| 003 | DE-627 | ||
| 005 | 20231225230800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/curroncol29010016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1119.xml |
| 035 | |a (DE-627)NLM335843468 | ||
| 035 | |a (NLM)35049690 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shalata, Walid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.03.2022 | ||
| 500 | |a Date Revised 24.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In the following report, we describe a case of alkaline phosphatase (ALP) elevation occurring during treatment with alectinib (Alecensa™), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastatic disease exhibited a rapid and significant response within a very short period to alectinib therapy, accompanied by a rapid increase of ALP to more than six times the upper limit of normal (grade 3) ALP, decreasing to within normal limits within 3 weeks after initiation of therapy without any dose modification | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ALK mutation | |
| 650 | 4 | |a Alecensa® (Alectinib) | |
| 650 | 4 | |a alkaline phosphatase (ALP) | |
| 650 | 4 | |a lung adenocarcinoma | |
| 650 | 4 | |a toxicity | |
| 650 | 7 | |a Carbazoles |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Alkaline Phosphatase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.1 |2 NLM | |
| 650 | 7 | |a alectinib |2 NLM | |
| 650 | 7 | |a LIJ4CT1Z3Y |2 NLM | |
| 700 | 1 | |a Yakobson, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Steckbeck, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Jama, Ashraf Abu |e verfasserin |4 aut | |
| 700 | 1 | |a Abu Saleh, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Agbarya, Abed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology (Toronto, Ont.) |d 1998 |g 29(2021), 1 vom: 31. Dez., Seite 173-177 |w (DE-627)NLM09444482X |x 1718-7729 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2021 |g number:1 |g day:31 |g month:12 |g pages:173-177 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/curroncol29010016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2021 |e 1 |b 31 |c 12 |h 173-177 | ||